Abstract:Objectives: The aim of this study is to investigate the population pharmacokinetics (PopPK) of cyclosporine (CsA) in the Chinese hematopoietic stem cell transplantation (HSCT) recipients for promoting the individualization of CsA administration. Methods: A total of 887 retrospective drug monitoring data points were collected from 58 HSCT recipients. Whole blood samples were collected at predose (C-0) and 2 hours (C-2) post dose. The administration of CsA was intermittent intravenous infusion, continuous intravenous infusion and oral. Population modeling was performed using the NONMEM (nonlinear mixed-effect modeling) program. A one compartment pharmacokinetic model was used to fit the data. Results: Body surface area (BSA), administration route and postoperative days were identified as significant covariates for clearance (CL) according to the final model: CL = 31.0 x (BsA/1.59)(0.761) x (ROUT) x (POD), where ROUT was 1.91 if the administration route was intravenous infusion, otherwise it is equal to 1. The POD was 0.818, 0.753, 0.539, and 0.509 for post-transplant Days 0 - 10, 11 - 20, 21 - 30 and more than 30 days, respectively. Administration route was a significant covariate for volume (V) according to the final model: V = 192 x (ROUT), where ROUT was 4.10, 3.63 and 1 when the administration route was continuous intravenous infusion, intermittent intravenous infusion and oral. The other covariates were not identified as a significant effect on CsA pharmacokinetic parameters. Conclusion: Body surface area, administration route and postoperative days should be considered in individual pharmacotherapy of cyclosporine for HSCT patient to achieve the desired therapeutic target.

Comparison between C2 and C0 as a monitoring tool for domestic cyclosporin A microemulsion capsule

Measurement of ciclosporin in whole blood by HPLC

Age Difference of Cyclosporin Dosage in Pediatric Patients

Pharmacokinetics of Mycophenolic Acid in Chinese Kidney Transplant Patients

Study on Blood Level Monitoring of CsA for Liver Transplantation Patients

Evaluation of the Area under the Curve of Enteric-Coated Mycophenolate Sodium Using a Limited Sampling Strategy in Chinese Kidney Transplant Recipients .

Comparison of peak and trough level monitoring of cyclosporine treatment using two modern cyclosporine preparations

Study of Ciclosporin Concentration in Blood of Kidney Transplantation Recipients

Therapeutic drug monitoring of cyclosporine and area under the curve prediction using a single time point strategy: appraisal using peak concentration data

Influencing Factors of Serum Concentration of Cyclosporin A

Population Pharmacokinetic Study of Cyclosporine in the Hematopoietic Stem Cell Transplant Recipients.

Cyclosporine A and Tacrolimus Combined with Enteric-Coated Mycophenolate Sodium Influence the Plasma Mycophenolic Acid Concentration - a Randomised Controlled Trial in Chinese Live Related Donor Kidney Transplant Recipients

Monitoring of Nuclear Factor of Activated T-cell-regulated Gene Expression in De Novo and Long-Term Liver Transplant Recipients Treated with Cyclosporine A.

Evaluation of Factors Related to Blood Concentration of Cyclosporine A in Adult Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Cyclosporine microemulsion C2 monitoring in Chinese heart transplant recipients

Retrospective study of two-hour post-dose cyclosporine level (C2) monitoring in long term maintenance phase of renal transplant recipients

Validation and evaluation of a newly developed time-resolved fluoroimmunoassay for cyclosporine quantitative analysis in human whole blood

Quantification of cyclosporine A in peripheral blood mononuclear cells by liquid chromatography-electrospray mass spectrometry using a column-switching approach

Pharmacokinetic and pharmacodynamic analysis of cyclosporine A (CsA) to find the best single time point for the monitoring and adjusting of CsA dose using twice-daily 3-h intravenous infusions in allogeneic hematopoietic stem cell transplantation

Correlation Between Blood Concentrations of Ciclosporin and Its Adverse Drug Reactions in Immunosuppressive Treatment of Hematopoietic Stem Cell Transplantation Recipients

Correlation Factors Influencing Blood Concentration of Ciclosporin A in Patients Underwent Liver Trans Plantation